Daily digest · Mon · 6 Apr 2026

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.

🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic

Hematologic Malignancies

PMID 41937093 · Bruton protein-tyrosine kinase (BTK) FDA-approved small molecule inhibitors used for the management of neoplastic and inflammatory disorders · 8/10 · 🟠 Comprehensive review of all 6 FDA-approved BTK inhibitors including 2025 landmark non-oncologic approvals (rilzabrutinib, remibrutinib), covering CLL, MCL, FL, MZL, WM

Early Cancer Detection (Liquid Biopsy, ctDNA, cfDNA)

PMID 41936819 · Certified Reference Materials for Standardization of cfDNA Isolation Recovery in Liquid Biopsy · 8/10 · 🔴 First certified reference materials for fragment-length-resolved cfDNA isolation standardization — addresses critical pre-analytical gap limiting liquid biopsy reliability

Topics with no 8+ articles today:

CBC-based diagnostics/ML: No results in CRDT window
AI/ML in diagnostics: Best candidate scored 7/10
Precision oncology: Best candidate scored 6/10
Novel therapeutics (immunotherapy/CAR-T): Best candidate scored 7/10
Cardiovascular-metabolic: Best candidate scored 4/10
Aging/longevity: Best candidate scored 4/10
Rare diseases: Best candidate scored 5/10 (title-only limited metadata)

🟢⚪ STANDARD (5-7) — Top by Topic

Early Cancer Detection

PMID 41936644 · Nucleosomal DNA-based reference materials for EGFR liquid biopsy · 7/10 · Diagnostics · 🟢 Near-term implementable PMID 41936750 · Blood-based MAVS biosensor for predicting immunotherapy response in SCLC · 7/10 · Diagnostics · ⚪ Promising preliminary ($5/test POCT)

AI/ML in Clinical Diagnostics

PMID 41936855 · Integrating Multi-Omics and AI for Personalized Breast Cancer Management · 7/10 · Diagnostics/Genomics

Hematologic Malignancies

PMID 41936620 · HCT outcomes for R/R MCL in the post-ibrutinib era (Japanese registry) · 6/10 · Treatment Innovation PMID 41936986 · Pristimerin drives ROS-dependent apoptosis in cutaneous T-cell lymphoma · 5/10 · Drug Development

Novel Therapeutics

PMID 41936892 · CAR-T to CAR-NK to CAR-M: progress and challenges in gene delivery systems · 6/10 · Treatment Innovation PMID 41936875 · Skin cancer treatment: conventional to nanotechnological approaches · 5/10 · Treatment Innovation

Precision Oncology

PMID 41936939 · Computational BRAF phosphoproteomic insights and regulatory networks in cancer · 6/10 · Genomics/Precision Medicine

💡 UNSOLICITED FINDS

None this run. Sentinel scan results were captured by topic-specific searches or scored <5.

📊 TODAY'S BREAKDOWN

By research category: Treatment Innovation (7), Diagnostics (4), Drug Development (3), Genomics/Precision Medicine (2)
By evidence maturity: Exploratory (9), Validated (7), Potentially Practice-Changing (0)
By source type: peer_reviewed 16 | preprint 0
By watchlist topic (reviewed/kept/highest):
- Hematologic malignancies: 10/4/8
- CBC diagnostics/ML: 0/0/0
- Early cancer detection: 10/3/8
- AI/ML diagnostics: 10/1/7
- Precision oncology: 10/1/6
- Novel therapeutics: 10/2/7
- Cardiovascular-metabolic: 10/0/4
- Aging/longevity: 10/0/4
- Rare diseases: 10/1/5
- Sentinel: 10/0/4
Topics with zero 8+ articles this run: CBC diagnostics/ML, AI/ML diagnostics, Precision oncology, Novel therapeutics, Cardiovascular-metabolic, Aging/longevity, Rare diseases

🔧 RUN NOTES

Monday run (Sunday CRDT window) — moderate yield typical of weekend indexing
No window expansion needed (≥5 relevant records found overall)
CBC-based diagnostics/ML topic returned 0 results — persistent zero-yield area (consider query expansion if pattern continues)
Aging/longevity had 161 raw results but overwhelmingly off-focus (general aging biology, not longevity interventions)
Cardiovascular-metabolic topic had 33 raw but no articles directly addressing GLP-1/SGLT2 outcomes at score ≥5
2 HIGH priority alerts emitted to Telegram